for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Illumina, Inc.

ILMN.O

Latest Trade

265.67USD

Change

5.74(+2.21%)

Volume

2,678,249

Today's Range

252.43

 - 

265.88

52 Week Range

252.43

 - 

380.76

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
259.93
Open
253.74
Volume
2,678,249
3M AVG Volume
23.04
Today's High
265.88
Today's Low
252.43
52 Week High
380.76
52 Week Low
252.43
Shares Out (MIL)
147.00
Market Cap (MIL)
38,209.71
Forward P/E
--
Dividend (Yield %)
--

Next Event

Illumina Inc at Cowen HealthCare Conference

Latest Developments

More

Illumina Reports Q4 Non-Gaap Earnings Per Share $1.70

Illumina And Roche Partner To Broaden Patient Access To Genomic Testing

Archerdx Announces Non-Exclusive, Multi-Year Partnership With Illumina

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Illumina, Inc.

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Contact Info

5200 Illumina Way

+1.858.2024500

https://www.illumina.com

Executive Leadership

Jay T. Flatley

Executive Chairman of the Board

Francis A. deSouza

President, Chief Executive Officer, Director

Sam A. Samad

Chief Financial Officer, Senior Vice President

Mostafa Ronaghi

Chief Technology Officer, Senior Vice President

Charles E. Dadswell

Senior Vice President, General Counsel, Secretary

Key Stats

2.05 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

2.8K

2018

3.3K

2019

3.5K

2020(E)

3.9K
EPS (USD)

2017

4.000

2018

5.720

2019

6.570

2020(E)

6.888
Price To Earnings (TTM)
38.59
Price To Sales (TTM)
10.78
Price To Book (MRQ)
8.28
Price To Cash Flow (TTM)
32.44
Total Debt To Equity (MRQ)
24.73
LT Debt To Equity (MRQ)
24.73
Return on Investment (TTM)
16.98
Return on Equity (TTM)
13.87

Latest News

Latest News

BRIEF-Illumina Files Additional Patent Infringement Suit Against BGI In The U.S.

* ILLUMINA FILES ADDITIONAL PATENT INFRINGEMENT SUIT AGAINST BGI IN THE U.S.

BRIEF-Scott Gottlieb Former U.S. FDA Commissioner, Joins Illumina’S Board Of Directors

* DR. SCOTT GOTTLIEB, FORMER US FDA COMMISSIONER, JOINS ILLUMINA’S BOARD OF DIRECTORS

BRIEF-Illumina And Roche Partner To Broaden Patient Access To Genomic Testing

* ILLUMINA AND ROCHE PARTNER TO BROADEN PATIENT ACCESS TO GENOMIC TESTING

Illumina abandons $1.2 billion deal to buy rival Pacific Biosciences

Illumina Inc <ILMN.O> on Thursday agreed to terminate the $1.2 billion (913.4 million pounds) deal to buy smaller rival Pacific Biosciences of California Inc <PACB.O>, weeks after the U.S. competition watchdog filed a complaint to block the purchase.

FTC files complaint to block Illumina from buying PacBio

The Federal Trade Commission has filed a complaint aimed at stopping Illumina Inc <ILMN.O> from purchasing Pacific Biosciences of California <PACB.O>, the agency said on Tuesday.

FTC files complaint to block Illumina from buying PacBio

The Federal Trade Commission has filed a complaint aimed at stopping Illumina Inc from purchasing Pacific Biosciences of California, the agency said on Tuesday.

BRIEF-Illumina Files Patent Infringement Suits Related To Bgi In Switzerland, Turkey And The Us

* ILLUMINA FILES PATENT INFRINGEMENT SUITS RELATED TO BGI IN SWITZERLAND, TURKEY AND THE US

UK's CMA refers Illumina-Pacific Biosciences deal for in-depth investigation

Britain's competition watchdog said on Thursday it would launch an in-depth investigation into the planned $1.2 billion merger between gene sequencing company Illumina Inc <ILMN.O> and smaller rival Pacific Biosciences of California Inc <PACB.O>.

UK's CMA says Illumina-Pacific Biosciences deal could hurt competition

Britain's competition watchdog said on Tuesday the planned $1.2 billion merger between gene sequencing company Illumina Inc and smaller rival Pacific Biosciences of California Inc may be a threat to competition in the country.

CMA says Illumina-Pacific Biosciences deal could hurt competition

Britain's competition watchdog said on Tuesday the planned $1.2 billion (£958 million) merger between gene sequencing company Illumina Inc and smaller rival Pacific Biosciences of California Inc may result in lessening of competition in the UK.

Illumina to buy rival Pacific Biosciences in $1.2 billion deal

Gene sequencing company Illumina Inc <ILMN.O> said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy smaller rival Pacific Biosciences of California Inc <PACB.O> in an all-cash deal valued...

Gene sequencing company Illumina to buy Pacific Biosciences in $1.2 billion deal

Gene sequencing company Illumina Inc <ILMN.O> said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy Pacific Biosciences of California Inc <PACB.O> in an all-cash deal valued at $1.2 billion...

BRIEF-Illumina Acquires Edico Genome To Accelerate Genomic Data Analysis

* ILLUMINA ACQUIRES EDICO GENOME TO ACCELERATE GENOMIC DATA ANALYSIS Source text for Eikon: Further company coverage:

BRIEF-Caredx Inc Enters Into A License And Commercialization Agreement With Illumina

* CAREDX INC - ON MAY 4, 2018, CO ENTERED INTO A LICENSE AND COMMERCIALIZATION AGREEMENT WITH ILLUMINA, INC - SEC FILING

BRIEF-Illumina Inc GAAP Earnings Per Share $1.41

* ILLUMINA REPORTS FINANCIAL RESULTS FOR FIRST QUARTER OF FISCAL YEAR 2018

BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies

* BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE COMPANION DIAGNOSTICS FOR BRISTOL-MYERS SQUIBB’S ONCOLOGY IMMUNOTHERAPIES

Loxo, Illumina to partner for diagnostic tool targeting cancer

Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

Loxo and Illumina in partnership over diagnostic for cancer drug

Loxo Oncology <LOXO.O> is partnering with genetic testing company Illumina Inc <ILMN.O> to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.

BRIEF-Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion Diagnostics

* LOXO ONCOLOGY AND ILLUMINA TO PARTNER ON DEVELOPING NEXT-GENERATION SEQUENCING-BASED PAN-CANCER COMPANION DIAGNOSTICS

BRIEF-Illumina Says CEO Francis Desouza's FY 2017 Total Compensation Was $8.8 Mln VS $8.4 Mln In FY 2016

* ILLUMINA SAYS PRESIDENT AND CEO FRANCIS DESOUZA'S FY 2017 TOTAL COMPENSATION WAS $8.8 MLN VS $8.4 MLN IN FY 2016 - SEC FILING Source text: [https://bit.ly/2H17H6F] Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up